NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
Clinical Trials
86 trialsNCT07478952 2026-03-18
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
ModernaTX, Inc.
Phase 1 Not yet recruiting
NCT03258567 2026-03-06
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06908096 2026-03-06
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03394365 2026-02-20
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07368634 2026-01-28
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07368153 2026-01-26
IDEP
University Hospital, Basel, Switzerland
Phase 2 Not yet recruiting
NCT07294547 2025-12-19
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Phase NA Recruiting
NCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT04664179 2025-12-12
CILESTE
Baylor College of Medicine
Phase 1 Recruiting
NCT07261215 2025-12-03
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT05683834 2025-11-21
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT05831111 2025-09-30
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT06909110 2025-08-14
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
Phase 1/2 Recruiting
NCT03266653 2025-08-08
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
Phase 2 Recruiting
NCT04013802 2025-08-08
TETRAVI
Baylor College of Medicine
Phase 1 Recruiting
NCT06926894 2025-07-31
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
Phase 1 Recruiting
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT04832607 2025-07-18
TRACE
University Hospital Freiburg
Phase 3 Recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06027879 2025-06-25
Gamma Capture
University of Pittsburgh
Phase 1/2 Enrolling by invitation
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05164094 2025-05-15
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT03475212 2025-05-11
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Phase 1/2 Active not recruiting
NCT06429800 2025-04-24
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
Atara Biotherapeutics
Phase 1 Withdrawn
NCT06682442 2025-04-20
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Phase NA Recruiting
NCT06870435 2025-03-11
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Sun Yat-sen University
Phase NA Recruiting
NCT05688241 2025-03-03
ESPECT
University Hospital, Basel, Switzerland
Phase 1/2 Not yet recruiting
NCT05183490 2024-12-30
R-MVST Cells for Treatment of Viral Infections
Columbia University
Phase 1 Recruiting
NCT03813394 2024-11-22
2018/00947
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT04308278 2024-10-30
EBVAST
Labo'Life
Phase 4 Recruiting
NCT02875613 2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
University of California, San Diego
Phase 2 Terminated
NCT05305040 2024-05-16
Prevent
AlloVir
Phase 2/3 Terminated
NCT04693637 2024-05-09
Prevent
AlloVir
Phase 2/3 Completed
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT03283826 2024-02-23
EMBOLD
Atara Biotherapeutics
Phase 1/2 Terminated
NCT06119256 2023-11-07
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1 Recruiting
NCT06075927 2023-10-10
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting
NCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed